FDA approved enlicitide (Lipfendra) in July. Merck's food and drink studies (CPT, 6 November) were run through an exposure-response model. Taken daily after a high-fat meal, predicted LDL-C lowering falls to 48%, against 64% fasted.
Key points
- Phase 3 rule: overnight fast, then 30 minutes before food or any drink but water
- Label: empty stomach, 30-minute wait; black coffee or plain tea allowed
- One fed or missed dose a week: 62 to 63% predicted
Our read: the Phase 3 dosing rule is what the label builds on, so for a food-sensitive oral drug we would model real-world food and missed-dose scenarios before the protocol is locked.
For your oral asset, who chose the Phase 3 dosing instruction: clinical, clinical pharmacology, or commercial?
In detail
Food cuts exposure. Coffee cuts less
- High-fat meal 30 minutes before the dose: exposure down 48% (model, steady state)
- Meal 4 hours before the dose, not an overnight fast: down 22% (model, steady state)
- Black coffee or plain tea: down 16% (model, steady state). Water volume: no meaningful effect
What the exposure loss means for LDL-C
One fed dose a week: 63%. One missed dose a week: 62%. Coffee or tea: 60%. Model predictions, not trial results.
Choose the dosing instruction before Phase 3
- Phase 3 tested an overnight fast and a 30-minute wait, water only. The label (July 2026) keeps the empty stomach and the wait
- The food and beverage studies ran alongside Phase 3. They added black coffee and plain tea
- For a food-sensitive oral drug, we would model real-world food and missed-dose scenarios before the protocol is locked
Sources
- doi.org: https://doi.org/10.1002/cpt.70541
- accessdata.fda.gov: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220848Orig1s000MultidisciplineR.pdf
- pmc.ncbi.nlm.nih.gov: https://pmc.ncbi.nlm.nih.gov/articles/PMC13743531/
- accessdata.fda.gov: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220848Orig1s000ltr.pdf
- accessdata.fda.gov: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220848Orig1s000lbl.pdf